HOLOGIC Reports Q3 FY2023 Revenue of $984.4 Million, Net Income of -$40.5 Million, Down 1.8% from Last Year

August 15, 2023

🌥️Earnings Overview

For the third quarter of fiscal year 2023 ending June 30 2023, HOLOGIC ($NASDAQ:HOLX) reported total revenue of USD 984.4 million and a net loss of USD 40.5 million, compared to total revenue of USD 228.4 million for the same period in the preceding year, representing a decrease of 1.8%.


GoodWhale is a great tool to analyze HOLOGIC‘s financials. The Star Chart shows that HOLOGIC is strong in assets and profitability, but medium in growth and weak in dividend. Since HOLOGIC is classified as a ‘rhino’, a company that has achieved moderate revenue or earnings growth, it is likely to be interesting to value-oriented investors who are looking for stable returns. Additionally, HOLOGIC has a high health score of 8/10, which means it is capable to safely ride out any crisis without the risk of bankruptcy. This makes it an attractive option for investors who are looking for lower volatility investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • HOLOGIC_Reports_Q3_FY2023_Revenue_of_984.4_Million_Net_Income_of_-40.5_Million_Down_1.8_from_Last_Year”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Hologic. HOLOGIC_Reports_Q3_FY2023_Revenue_of_984.4_Million_Net_Income_of_-40.5_Million_Down_1.8_from_Last_Year”>More…

    Total Revenues Net Income Net Margin
    4.04k 484.1 13.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Hologic. HOLOGIC_Reports_Q3_FY2023_Revenue_of_984.4_Million_Net_Income_of_-40.5_Million_Down_1.8_from_Last_Year”>More…

    Operations Investing Financing
    961.1 -128.2 -442.4
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Hologic. HOLOGIC_Reports_Q3_FY2023_Revenue_of_984.4_Million_Net_Income_of_-40.5_Million_Down_1.8_from_Last_Year”>More…

    Total Assets Total Liabilities Book Value Per Share
    9.34k 4.16k 21.16
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Hologic are shown below. HOLOGIC_Reports_Q3_FY2023_Revenue_of_984.4_Million_Net_Income_of_-40.5_Million_Down_1.8_from_Last_Year”>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    7.0% 19.7% 19.3%
    FCF Margin ROE ROA
    20.6% 9.3% 5.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s products are used in a variety of settings, including hospitals, clinics, and physician offices. Hologic also provides a range of services, including support, training, and education. The company has a strong presence in the United States and international markets, and its products are backed by a large body of scientific research. ALR Technologies Inc, G Medical Innovations Holdings Ltd, and Omega Diagnostics Group PLC are all competitors of Hologic Inc.

    – ALR Technologies Inc ($OTCPK:ALRT)

    ALR Technologies Inc is a publicly traded company with a market capitalization of $19.32 million as of 2022. The company has a return on equity of 17.26%. ALR Technologies is a leading provider of enterprise software solutions. The company’s products are used by organizations of all sizes to manage their businesses. ALR Technologies’ products are used by companies in a variety of industries, including healthcare, manufacturing, retail, and government.

    – G Medical Innovations Holdings Ltd ($NASDAQ:GMVD)

    As of 2022, Aetna’s market cap was 5.58M and its ROE was 783.79%. Aetna is a diversified healthcare benefits company that offers a broad range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans.

    – Omega Diagnostics Group PLC ($LSE:ODX)

    Omega Diagnostics Group PLC is a medical diagnostics company. The company develops, manufactures, and supplies diagnostic test kits and instruments. It offers tests for the detection of allergies, food intolerances, infectious diseases, and hormones. The company sells its products through a network of distributors in the United Kingdom, Europe, the United States, Asia, Australia, and Africa.


    HOLOGIC reported a decrease in total revenue from $228.4 million to $984.4 million for the third quarter of Fiscal Year 2023, ending June 30 2023, along with a net income of -$40.5 million. This data indicates that investing in HOLOGIC would not be a sound investment. Investors should consider the decreased revenue and net income when deciding whether to invest in the company or not.

    Factors such as market trends and industry developments should also be taken into account. Overall, HOLOGIC is not an ideal choice for investors looking to maximize their return on investment.

    Recent Posts

    Leave a Comment